

## **YK250 Human GIP (Active) ELISA**

**FOR LABORATORY USE ONLY**

<Distributed by>

**SCETI** SCETI K.K.

**Kasumigaseki place, 3-6-7, Kasumigaseki, Chiyoda-ku,  
Tokyo 100-0013 Japan**

**<http://www.sceti.co.jp/english/export> e-mail exp-pet@sceti.co.jp**

|               |                                    | <b>Contents</b> |             |
|---------------|------------------------------------|-----------------|-------------|
| <b>I .</b>    | <b>Introduction</b>                |                 | <b>2</b>    |
| <b>II .</b>   | <b>Characteristics</b>             |                 | <b>3</b>    |
| <b>III .</b>  | <b>Composition</b>                 |                 | <b>4</b>    |
| <b>IV .</b>   | <b>Method</b>                      |                 | <b>5-6</b>  |
| <b>V .</b>    | <b>Notes</b>                       |                 | <b>7</b>    |
| <b>VI .</b>   | <b>Performance Characteristics</b> |                 | <b>8-11</b> |
| <b>VII .</b>  | <b>Stability and Storage</b>       |                 | <b>12</b>   |
| <b>VIII .</b> | <b>References</b>                  |                 | <b>12</b>   |

– Please read all the package insert carefully before beginning the assay –

## YK250 Human GIP (Active) ELISA

### I . Introduction

The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagons-like peptide-1 (GLP-1), are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after ingestion of food.

The intestinal peptide GIP was first isolated from porcine upper small intestine<sup>1)</sup>. The sequences of porcine<sup>2) 3)</sup>, bovine<sup>4)</sup> and human GIP<sup>5)</sup> have been determined, each has 42 amino acids, and the sequences is highly conserved. The porcine and bovine peptides differ from the human at two and three site, respectively. Takeda et al. have isolated a human cDNA encoding the GIP precursor and confirming that GIP belongs to the vasoactive intestinal peptide (VIP)/Glucagon/secretin family<sup>6)</sup>. GIP is a gastrointestinal peptide hormone that is released from duodenal endocrine K cells after absorption of glucose or fat<sup>7)</sup>. GIP is a potent releaser of insulin in experimental animals<sup>8)</sup> and in man<sup>9,10)</sup> provided that the blood glucose is above basal level. Plasma level of GIP is elevated after an oral glucose load or a meal in normal man. This increase after a meal is below normal in newly diagnosed insulin-dependent diabetics<sup>11)</sup>. It is now being recognized that GIP receptor is also expressed in organs and cells such as duodenum, small intestine, pancreatic alpha-cell, adipocyte and osteoblast. These results demonstrate GIP may have a lot of physiological effect in addition to their glucoregulatory effects<sup>12,13,14,15)</sup>. GIP is rapidly inactivated by the enzyme dipeptidyl peptidase- 4 (DPP- 4) to GIP (3-42) with a blood half-life of only several minutes. DPP- 4 inhibitor can prolong the half-life of GIP, that expecting treatment of incretin effect.

This ELISA kit has high specificity to human GIP (1-42) active form and shows no crossreactivity to human GIP (3-42) inactive form.

| YK250 Human GIP (Active) ELISA Kit  | Contents                           |
|---|------------------------------------|
| ▼ The assay kit can measure human GIP (1-42) active form in plasma within the range of 3.9~ 250 pg/mL. (0.78~50.2 pM)   | 1) Antibody coated plate           |
| ▼ The assay is completed within 2hr+1hr+0.5hr.  | 2) Standard                        |
| ▼ With one assay kit, 40 samples can be measured in duplicate.  | 3) HRP labeled antibody solution   |
| ▼ Test sample: Human plasma (EDTA-2Na + DPP-4 inhibitor) and culture medium supernatant<br>Sample volume: 50 µL   | 4) Enzyme substrate solution (TMB) |
| ▼ The 96-wells plate in kit is consisted by 8-wells strips, and the strips can be used separately.  | 5) Stopping solution               |
| ▼ Stability and storage<br>Store all of the components at 2-8°C.<br>The kit is stable under the condition for 18 months from the date of manufacturing.<br>The expiry date is stated on the label of kit. | 6) Buffer solution                 |
|   | 7) Washing solution (concentrated) |
|   | 8) Adhesive foil                   |

## **II. Characteristics**

This ELISA kit is used for quantitative determination of human GIP (1-42) active form in plasma and culture medium supernatant. The kit is characterized by its sensitive quantification and high specificity. In addition, it has no influence by other components in samples. GIP (1-42) standard is highly purified synthetic product.

### **< Specificity >**

This ELISA kit has high specificity to human GIP (1-42) active form and shows no cross reactivity to human GIP (3-42) inactive form, glucagons, human GLP-2, GLP-1 (7-36) NH<sub>2</sub> and GLP-1 (9-36) NH<sub>2</sub>.

### **< Assay principle >**

This ELISA kit for determination of human GIP (1-42) active form is based on a sandwich enzyme immunoassay. To the wells of plate coated with highly purified mouse monoclonal antibody against human GIP (1-42) active form, standards or samples are added for the 1st step immunoreaction. After the 1st step incubation and plate washing, HRP labeled antibody solution against human GIP (1-42) is added as the 2nd step to form antibody - antigen - labeled antibody complex on the surface of the wells. After the 2nd step incubation and rinsing out excess labeled antibody, Finally, HRP enzyme activity is determined by 3,3',5,5'-Tetramethylbenzidine (TMB) and the concentration of human GIP (1-42) active form is calculated.

### III. Composition

| Component                          | Form             | Quantity           | Main Ingredient                                       |
|------------------------------------|------------------|--------------------|---|
| 1. Antibody coated plate           | microtiter plate | 1 plate (96 wells) | Mouse anti GIP (1-42) monoclonal antibody coated      |
| 2. Standard                        | lyophilized      | 1 vial (500 pg)    | Synthetic human GIP (1-42)                            |
| 3. HRP labeled antibody solution   | liquid           | 1 bottle (12 mL)   | HRP labeled mouse anti GIP (1-42) monoclonal antibody |
| 4. Enzyme substrate solution       | liquid           | 1 bottle (12 mL)   | 3,3',5,5'-Tetramethylbenzidine (TMB)                  |
| 5. Stopping solution               | liquid           | 1 bottle (12 mL)   | 1M H <sub>2</sub> SO <sub>4</sub>                     |
| 6. Buffer solution                 | liquid           | 1 bottle (25 mL)   | Buffer containing a reaction accelerator              |
| 7. Washing solution (concentrated) | liquid           | 1 bottle (50 mL)   | Concentrated saline                                   |
| 8. Adhesive foil                   |                  | 3 pieces           |   |

#### **IV. Method**

##### < Equipment required >

1. Photometer for microtiter plate (plate reader) which can read extinction 3.0 at 450nm
2. Microtiter plate shaker
3. Washing device for microtiter plate and dispenser with aspiration system
4. Micropipettes, multi-channel pipettes for 8 wells or 12 wells and their tips
5. Glass test tubes for preparation of standard solution
6. Graduated cylinder (1,000 mL)
7. Distilled water or deionized water

##### < Preparatory work >

1. Preparation of standard solution:  
Reconstitute the human GIP (1-42) standard with 1 mL of buffer solution, which affords 500 pg/mL standard solution. The reconstituted standard solution (0.2 mL) is diluted with 0.2 mL of buffer solution that yields 250 pg/mL standard solution. Repeat the dilution procedure to make each standard solution of 125, 62.5, 31.3, 15.6, 7.8 and 3.9 pg/mL. Buffer solution itself is used as 0 pg/mL standard solution. If a sample concentration below 3.9 pg/mL is predicted, standard curve may be further set up a lower detection limit by using 2.0 pg/mL standard solution which can be prepared by 2-fold dilution of 3.9 pg/mL standard solution.
2. Preparation of washing solution:  
Dilute 50 mL of washing solution (concentrated) to 1,000 mL with distilled or deionized water.
3. Other reagents are ready for use.

##### < Procedure >


1. Before starting the assay, bring all the reagents and samples to room temperature (20 ~ 30°C).
2. Fill 0.35 mL/well of washing solution into the wells and aspirate the washing solution in the wells. Repeat this washing procedure further twice (total 3 times). Finally, invert the plate and tap it onto an absorbent surface, such as paper toweling, to ensure blotting free of most residual washing solution.

3. Add 50 $\mu$ L of buffer solution to the wells first, and then introduce 50 $\mu$ L of each of standard solutions (0, 3.9, 7.8, 15.6, 31.3, 62.5, 125 and 250 pg/mL) or samples to the wells.
4. Cover the plate with adhesive foil and incubate it at room temperature for 2 hours. During the incubation, the plate should be shaken with a plate shaker (approximately 100 rpm).
5. After incubation, take off the adhesive foil, aspirate and wash the wells 4 times with 0.35 mL/well of washing solution. Finally, invert the plate and tap it onto an absorbent surface, such as paper toweling, to ensure blotting free of most residual washing solution.
6. Add 100 $\mu$ L of HRP labeled antibody solution to each of the wells.
7. Cover the plate with adhesive foil and incubate it at room temperature for 1 hour. During the incubation, the plate should be shaken with a plate shaker (approximately 100 rpm).
8. Take off the adhesive foil, aspirate and wash the wells 4 times with 0.35 mL/well of washing solution. Finally, invert the plate and tap it onto an absorbent surface, such as paper toweling, to ensure blotting free of most residual washing solution.
9. Add 100 $\mu$ L of Enzyme substrate solution (TMB) to each of the wells, cover the plate with adhesive foil and keep it for 30 minutes at room temperature in a dark place for color reaction (keep still, plate shaker not need).
10. Add 100  $\mu$ L of stopping solution to each of the wells to stop color reaction.
11. Read the optical absorbance of the solution in the wells at 450 nm. The dose-response curve of this assay fits best to a 5 (or 4)-parameter logistic equation. The results of unknown samples can be calculated with any computer program having a 5 (or 4)-parameter logistic function. Otherwise calculate mean absorbance values of wells containing standards and plot a standard curve on double logarithmic graph paper (abscissa: concentration of standard; ordinate: absorbance values). Use the average absorbance of each sample to determine the corresponding value by simple interpolation from this standard curve.

## V. Notes

1. EDTA-2Na additive blood collection tube is recommended for the plasma collection. After blood is collected, add DPP-4 inhibitor (0.01mL per milliliter of blood, Catalog No. DPP4 MILLIPORE) to collection tube immediately. Alternatively BD<sup>TM</sup> P800 Venous Blood Collection Tubes for plasma GLP-1, GIP, Glucagon, Ghrelin (Becton, Dickinson) can be used. Plasma samples must be used as soon as possible after collection. If the samples are tested later, they should be divided into test tubes in small amount and frozen at or below -30°C. Avoid repeated freezing and thawing of samples.
2. Standard solutions should be prepared immediately before use. This kit can be used dividedly in strips of the plate. In such case, the rest of reconstituted reagent (standard) should be stored at or below -30°C (stable for 2 months).
3. During storage of washing solution (concentrated) at 2-8°C, precipitates may be observed, however, they will be dissolved when diluted.
4. Pipetting operations may affect the precision of the assay, so that pipette standard solutions or samples precisely into each well of plate. In addition, use clean test tubes or vessels in assay and use new tip for each standard or sample to avoid cross contamination.
5. When sample concentration exceeds 250 pg/mL, it needs to be diluted with buffer solution to proper concentration.
6. During the incubation except the color reaction, the plate should be shaken gently by a plate shaker to promote immunoreaction (approximately 100 rpm).
7. Perform all the determination in duplicate.
8. Read plate optical absorbance of reaction solution in wells as soon as possible after stop color reaction.
9. To quantitate accurately, always run a standard curve when testing samples.
10. Protect reagents from strong light (e.g. direct sunlight) during storage and assay.
11. Satisfactory performance of the test is guaranteed only when reagents are used from combination pack with identical lot number.

## VI. Performance Characteristics



### <Analytical Recovery>

#### <Human plasma A>

| Added GIP (pg/ml) | Observed (pg/ml) | Expected (pg/ml) | Recovery (%) |
|-------------------|------------------|------------------|--------------|
| 0                 | 14.3             |                  |              |
| 5                 | 18.1             | 19.3             | 93.8         |
| 25                | 37.6             | 39.3             | 95.7         |
| 100               | 111.8            | 114.3            | 97.8         |

#### <Human plasma B>

| Added GIP (pg/ml) | Observed (pg/ml) | Expected (pg/ml) | Recovery (%) |
|-------------------|------------------|------------------|--------------|
| 0                 | 26.7             |                  |              |
| 5                 | 32.7             | 31.7             | 103.2        |
| 25                | 46.5             | 51.7             | 89.9         |
| 100               | 110.5            | 126.7            | 87.2         |

#### <Human plasma C>

| Added GIP (pg/ml) | Observed (pg/ml) | Expected (pg/ml) | Recovery (%) |
|-------------------|------------------|------------------|--------------|
| 0                 | 9.4              |                  |              |
| 5                 | 12.9             | 14.4             | 89.6         |
| 25                | 30.2             | 34.4             | 87.8         |
| 100               | 108.1            | 109.4            | 98.8         |

**<Human plasma D>**

| Added GIP<br>(pg/ml) | Observed<br>(pg/ml) | Expected<br>(pg/ml) | Recovery<br>(%) |
|----------------------|---------------------|---------------------|-----------------|
| 0                    | 22.1                |                     |                 |
| 5                    | 27.2                | 27.1                | 100.4           |
| 25                   | 47.1                | 47.1                | 100.0           |
| 100                  | 113.8               | 122.1               | 93.2            |

**<Human plasma E>**

| Added GIP<br>(pg/ml) | Observed<br>(pg/ml) | Expected<br>(pg/ml) | Recovery<br>(%) |
|----------------------|---------------------|---------------------|-----------------|
| 0                    | 9.3                 |                     |                 |
| 5                    | 13.4                | 14.3                | 93.7            |
| 25                   | 32.8                | 34.3                | 95.6            |
| 100                  | 109.9               | 109.3               | 100.5           |

**<Dilution test - 1>****<Human plasma A>**

| Sample dilution | Observed<br>(pg/ml) | Expected<br>(pg/ml) | % of Expected<br>(%) |
|-----------------|---------------------|---------------------|----------------------|
| X1              | 72.1                | 72.1                |                      |
| X2              | 36.4                | 36.1                | 100.8                |
| X4              | 19.4                | 18.0                | 107.8                |
| X8              | 10.0                | 9.0                 | 111.1                |

**<Human plasma B>**

| Sample dilution | Observed<br>(pg/ml) | Expected<br>(pg/ml) | % of Expected<br>(%) |
|-----------------|---------------------|---------------------|----------------------|
| X1              | 46.3                | 46.3                |                      |
| X2              | 24.8                | 23.1                | 107.3                |
| X4              | 12.8                | 11.6                | 110.6                |
| X8              | 7.6                 | 5.8                 | 131.0                |

**<Human plasma C>**

| Sample dilution | Observed<br>(pg/ml) | Expected<br>(pg/ml) | % of Expected<br>(%) |
|-----------------|---------------------|---------------------|----------------------|
| X1              | 30.1                | 30.1                |                      |
| X2              | 14.7                | 15.0                | 98.0                 |
| X4              | 8.0                 | 7.5                 | 106.7                |

**<Human plasma D>**

| Sample dilution | Observed<br>(pg/ml) | Expected<br>(pg/ml) | % of Expected<br>(%) |
|-----------------|---------------------|---------------------|----------------------|
| X1              | 20.9                | 20.9                |                      |
| X2              | 11.1                | 10.5                | 105.7                |
| X4              | 6.2                 | 5.2                 | 119.2                |

**<Human plasma E>**

| Sample dilution | Observed (pg/ml) | Expected (pg/ml) | % of Expected (%) |
|-----------------|------------------|------------------|-------------------|
| X1              | 30.2             | 30.2             |                   |
| X2              | 15.9             | 15.1             | 105.3             |
| X4              | 8.9              | 7.6              | 117.1             |

**<Dilution test - 2> GIP (1-42) concentration in plasma for 40 min. after a meal****<Human plasma A>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | Over             |                       |              |
| X4              | 171.7            | 686.8                 |              |
| X8              | 82.5             | 660.2                 | 673.5        |

**<Human plasma B>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | Over             |                       |              |
| X4              | 234.5            | 938.0                 |              |
| X8              | 123.6            | 989.0                 | 963.5        |

**<Human plasma C>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | Over             |                       |              |
| X4              | Over             |                       |              |
| X8              | 206.3            | 1650.2                | 1650.2       |

**<Human plasma D>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | Over             |                       |              |
| X4              | Over             |                       |              |
| X8              | 128.2            | 1025.5                | 1025.5       |

**<Human plasma E>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | Over             |                       |              |
| X4              | 165.8            | 663.1                 |              |
| X8              | 88.8             | 710.4                 | 686.8        |

**<Human plasma F>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | 166.5            | 332.9                 |              |
| X4              | 82.3             | 329.1                 |              |
| X8              | 40.4             | 322.9                 | 328.3        |

**<Human plasma G>**

| Sample dilution | Observed (pg/ml) | Concentration (pg/ml) | Mean (pg/ml) |
|-----------------|------------------|-----------------------|--------------|
| X1              | Over             |                       |              |
| X2              | 240.8            | 481.6                 |              |
| X4              | 123.6            | 494.3                 |              |
| X8              | 64.5             | 515.7                 | 497.2        |

**<Crossreactivity>**

| Related peptides             | Crossreactivity (%) |
|------------------------------|---------------------|
| GIP (1-42) (Human)           | 100                 |
| GIP (3-42) (Human)           | <0.1                |
| Glucagon                     | <0.1                |
| Human GLP-2                  | <0.1                |
| GLP-1 (7-36) NH <sub>2</sub> | <0.1                |
| GLP-1 (9-36) NH <sub>2</sub> | <0.1                |

**< Precision and reproducibility >**

| Test sample  | Intra-assay CV (%) | Inter-assay CV (%) |
|--------------|--------------------|--------------------|
| Human plasma | 5.2 ~ 6.5          | 2.6 ~ 5.6          |

**<Assay range>**

3.9 ~ 250 pg/mL (0.78~50.2 pM)

## VII. Stability and Storage

- < Storage > Store all of the components at 2-8°C.
- < Shelf life > The kit is stable under the condition for 18 months from the date of manufacturing.  
The expiry date is stated on the label of kit.
- < Package > For 96 tests per one kit including standards

## VIII. References

1. Brown, J.C., Mutt, V. and Pedersen, R.A. (1970) Further purification of a polypeptide demonstrating enterogastrone activity. *J. Physiol.* **209**, 57-64
2. Jörnvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, Mutt V. (1981) Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). *FEBS Lett.* **123**, 205-210.
3. Moody, A.J., Damm Jorgensen, K. and Thim, L. (1981) *Diabetologia* **21**, 306, abstr.
4. Carlquist M, Maletti M, Jörnvall H, Mutt V. (1984) A novel form of gastric inhibitory polypeptide (GIP) isolated from bovine intestine using a radioreceptor assay. Fragmentation with staphylococcal protease results in GIP1-3 and GIP4-42, fragmentation with enterokinase in GIP1-16 and GIP17-42. *Eur. J. Biochem.* **145**, 573-577
5. Moody, A. J., Thim, L. & Valverde, I. (1984) The isolation and sequencing of human gastric inhibitory peptide (GIP). *FEBS Lett.* **172**, 142-148
6. Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, Tobe T, et al. (1987) Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. *Proc Natl Acad Sci U S A.* **84**(20):7005-8.
7. Pederson, R.A. (1994) in *Gut Peptides: Biochemistry and Physiology*, eds, Walsh, J.H. & Dockray, G.J. (Raven, New York), pp, 217-260
8. Rabinovitch, A. and Dupre, J (1974) Effect of the gastric inhibitory polypeptide present in impure pancreatico-cholecystokinin on plasma insulin and glucagons in the rat. *Endocrinology* **94**, 1139-1144
9. Dupre, J., Ross, S.A., Watson, D. and Brown, J.C. (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. *J. Clin. Endocrinol. Metab.* **37**, 826-828
10. Elahi, D., Andersen, D.K., Brown, J.C., Debas, H.T., Hershcopf, R.J., Raizes, G.S., Tobin, J.D. and Andres, R. (1979) Pancreatic alpha-and-beta-cell response to GIP infusion in normal man. *Am. J. Physiol.* **237**, E185-E191
11. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L. (1983) Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. *J Clin Endocrinol Metab.* **56**, 1306-12.
12. Naitoh R, Miyawaki K, Harada N, Mizunoya W, Toyoda K, Fushiki T, Yamada Y, Seino Y, Inagaki N. (2008) Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. *Biochem Biophys Res Commun.* **376**, 21-5.
13. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M,

- Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y. (1999) Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. *Proc Natl Acad Sci U S A.* **96**, 14843-7.
14. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y.(2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat Med.* **8**, 738-42.
  15. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y. (2006) Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. *Mol Endocrinol.* **20**, 1644-51.

<Manufacturer>

Yanaihara Institute Inc.

2480-1 Awakura, Fujinomiya-shi

Shizuoka, Japan 418-0011

TEL: +81-544-22-2771 FAX: +81-544-22-2770

Website: <http://www.yanaihara.co.jp> E-mail: [ask@yanaihara.co.jp](mailto:ask@yanaihara.co.jp)

Update at June 24, 2014